tbuckley/cabot-search huggingface dataset:
A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC?
Authors: Lina Pugliano, Dimitrios Zardavas, Marianne Paesmans, Ivana Sestak, Richard D. Gelber, Jack M. Cuzick, Mitchell Dowsett, Ahmad Awada, Martine J. Piccart-Gebhart, Evandro De Azambuja
Journal: Journal of Clinical Oncology (2013)

575 Background: Obesity is an adverse prognostic factor in BC. Mixed results are reported for the relative efficacy of AIs compared to tamoxifen (T) in obese ER+ BC patients. Our purpose was to conduct a meta-analysis of adjuvant randomised trials of AIs vs T assessing the impact of body mass index (BMI). Methods: We identified four studies evaluating BMI and endocrine therapy. Of these, 3 were randomised (non-steroidal AIs vs T) and were evaluable for the aggregation of results for DFS and OS in our meta-analysis. We extracted published data from ATAC, ABCSG-12 and BIG01-98, analyzed according to standard meta-analytic techniques. Results: A total of 11,383 patients were included in our study. BMI&gt;25 is associated with reduced disease free survival (DFS) and a trend towards worse overall survival (OS) (Table 1). A significantly shorter DFS was seen for patients with BMI&gt;25 treated with an AI while a trend was seen for OS. Reduced relative efficacy was seen for DFS for AIs compared to T for BMI&lt;25 (HR=0.78; 95%CI 0.66- 0.91; p=0.002) and a trend for BMI&gt;25 (HR=0.85; 95%CI 0.70- 1.02; p=0.08). The test for interaction was not significant (p=0.48), with similar results for OS for BMI&lt;25 (HR=0.79; 95%CI 0.63-0.9; p=0.009) and BMI&gt;25 (HR=0.98; 95%CI 0.61-1.60; p=0.95). The test for interaction was not significant (p=0.37). Notably, significant heterogeneity in patients treated with anastrozole and a BMI&gt;25 did not allow a comparison between anastrozole and letrozole. Conclusions: BMI&gt;25 has a negative prognostic effect in BC. AIs demonstrate improved outcomes in normal weight BC patients (BMI&lt;25). Obesity was associated with observed relative reduced efficacy of AIs; however, we were not able to detect a significant interaction between BMI and treatment effect. Further analyses into the differing impact of type of AIs on BC outcomes in obese patients are warranted. [Table: see text]
PRESENCE OF MID-MYOCARDIAL SUBSTRATE IS ASSOCIATED WITH NEED FOR MULTIPLE ABLATIONS IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY AND VENTRICULAR ARRHYTHMIAS
Authors: Peter Rothstein, Michael Cowherd, Matthew Zipse, Ryan Borne, Jehu Mathew, Alexis Tumolo, Amneet Sandhu, Duy Nguyen, Lucas Marzec, Ryan Aleong, Christine Tompkins, William Sauer, Wendy Tzou
Journal: Journal of the American College of Cardiology (2017)
The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).
Authors: Barbara F. Eichhorst, Kirsten Fischer, Anna- Maria Fink, Thomas Elter, Clemens M Wendtner, Raymonde Busch, Michael Hallek
Journal: Blood (2008)
Assessing the Effects of Psychotherapy
Authors: Rolf Sandell
Journal: Psychotherapy and Psychosomatics (1987)

On the basis of an explication of the experimental method of control for causal order and spuriousness, nonexperimental alternatives are explored. Controlling for both causal order and spuriousness, the partial correlation approach is explained, particularly as developed in structural equation models. Advantages and disadvantages in comparison with the experimental method are discussed.
ASSOCIATION BETWEEN SHORT AND LONG SLEEP DURATION AND CARDIOVASCULAR OUTCOMES? A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Chayakrit Krittanawong, Anusith Tunhasiriwet, Zhen Wang, Hongju Zhang, Larry J. Prokop, Sakkarin Chirapongsathorn, Mehmet Aydar, Tao Sun, Takeshi Kitai
Journal: Journal of the American College of Cardiology (2017)
Abstract P291: The Ubiquitin Ligase Siah2 in Cardiac Response to Ischemia
Authors: Maria C Scimia, Hyungsoo Kim, David Bowtell, Mark Mercola, Ze'ev A Ronai
Journal: Circulation Research (2011)

Background: The E3 ubiquitin ligases SIah1 and 2 mediate a cellular response to hypoxia through its control of prolyl-hydroxylases and consequently HIF1α stability. Given the impact of hypoxia on heart function under stress, we have evaluated the effect of genetic deletion of Siah1 and 2 on cardiac function in response to myocardial infarction. Objective: To determine the physiological significance of the ubiquitin ligase Siah genes under in vivo ischemia condition. Materials and methods: To substantiate the role of Siah2 in ischemia-induced cell death, we tested difference in the response of myocardial tissue to ischemia using Siah1a +/− /Siah2 −/− mutant mice and their wildtype littermates. Analysis of heart tissue from Siah1a +/− /Siah2 −/− mice subjected to a model of 24 hours anterior descending coronary artery occlusion revealed their resistance to ischemic injury when compared with their littermates. Cardiac function, measured as EF %, was significantly less impaired in the mutant mice. Heart tissue obtained from Siah1a +/− /Siah2 −/− mice subjected to myocardial ischemia, exhibited a significantly lower degree of apoptosis (Tunel Staining), and myocardial infarct size (Evans blue, TTC). Conclusions: Collectively, these data establish that reduced expression of Siah1/2 exerts a cardioprotective function under ischemic conditions. The underlying molecular mechanisms linking cardioprotection to ischemic challenge will be discussed.
ECONOMIC IMPLICATIONS OF LATE DISCHARGE AFTER TRANSCATHETER AORTIC CATHETER IMPLANTATION
Authors: Sagar Mallikethi-Reddy, Emmanuel Akintoye, Alexandros Briasoulis, Naveen Trehan, Shanker Kundumadam, Anupama Kottam, Shaun Cardozo, Melvyn Rubenfire, Luis Afonso, Cindy Grines
Journal: Journal of the American College of Cardiology (2017)
An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.
Authors: Julie Toplin, Courtney Fuller, Linda Fletcher, Stephane Wong, Peter Maslak, Jorge Cortes, Rosemary Mazanet, Susan Branford, Timothy Hughes, Chad Galderisi, Michael Heinrich, Brian Druker, Emmanuel Beillard
Journal: Blood (2007)
Plasma level of soluble Fms-like tyrosine kinase 1 (sFIt-1) as a predictive marker of acute severe heart failure in patients with acute myocardial infarction
Authors: Onoue K, Takemoto Y, Iwama H, Somekawa S, Okayama S, Ishigami K, Takeda Y, Kawata H, Horii M, Nakajima T, Uemura S, Saito Y
Journal: Circulation (2007)

BACKGROUND: We previously reported that acute cardiac over-expression of placental growth factor (PlGF) contributed to the improvement of cardiac function in patients with acute myocardial infarcti...
A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)
Authors: M. H. Kulke, D. Niedzwiecki, M. A. Tempero, D. R. Hollis, R. J. Mayer
Journal: Journal of Clinical Oncology (2004)

4011 Background: In the treatment of advanced pancreatic cancer, chemotherapy regimens utilizing prolonged infusions of gemcitabine or combinations of gemcitabine and other agents have been associated with higher objective tumor response rates and, in some cases, improvements in progression-free survival when compared with gemcitabine administered as a standard 30-minute infusion. Comparisons between these novel regimens have been limited. We therefore performed a randomized phase II study of four investigational chemotherapy regimens in pts with documented metastatic pancreatic cancer. Methods: Pts were randomized to receive one of the following four treatments: gem 1000 mg/m2 d 1, 8, 15 with cisplatin 50 mg/m2 d1, 15 q 28d (Arm A); gem 1500 mg/m2 at a fixed dose rate of 10 mg/m2/minute d1, 8, 15 q 28d (Arm B); gem 1000 mg/m2 d1, 8 with docetaxel 40 mg/m2 d1, 8 q 21d (Arm C); or gem 1000 mg/m2 d1, 8 with irinotecan 100 mg/m2 d1, 8 q 21d (Arm D). Planned follow up per pt is 6 months. Results: Two hundred and fifty-one pts (61–65 per arm) were enrolled, with the following characteristics: median age 60.7 (range (31–84); M/F = 157/94; ECOG PS 0/1/2 = 49/86/18. Median follow-up time is 4.8 months. Pts were followed for overall survival, tumor response, time to tumor progression, and toxicity. The major toxicities experienced by 198 enrolled pts for whom data is currently available are shown in Table 1. Three pts experienced treatment related deaths: 1 (2%) in Arm A and 2 (4%) in Arm B. Conclusions: While the specific toxicities differ to some degree between regimens, all four regimens have acceptable toxicity profiles. Accrual to the trial has been completed. Updated toxicity data, as well as preliminary data for survival, response, and time to tumor progression will be presented at the annual meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Pharmaceuticals
Dual Role of Soluble Urokinase Plasminogen Activator Receptor Released by the Paroxysmal Nocturnal Hemoglobinuria Cell in Stimulation of Proliferation and Inhibitor of Apoptosis of PNH Cells but Suppression of Normal Phenotype Cell Growth.
Authors: Elaine M. Sloand, Simant Shah, Young Neal
Journal: Blood (2005)
PREVALENCE AND RISK INDICATORS OF SYMPTOMS OF COMMON MENTAL DISORDERS AMONG DUTCH OLYMPIC ATHLETES
Authors: Vincent Gouttebarge, Jonkers Ruud, Moen Maarten, Verhagen Evert, Paul Wylleman, Gino Kerkhoffs
Journal: British Journal of Sports Medicine (2017)

Background In the past years, symptoms of common mental disorders have been exponentially under study among professional i.e. elite athletes. Two recent cross-sectional studies among Australian and French elite Olympic athletes have showed a prevalence of symptoms of common mental disorders in the range of 17 to 45%. Objective To determine the prevalence and comorbidity of symptoms of common mental disorders (distress, anxiety/depression, sleep disturbance, eating disorders, adverse alcohol use) among Dutch elite athletes, and to explore the inference between potential risk indicators (severe injury, surgery, life events, sport career dissatisfaction, social support) and the outcomes measures under study. Design Cross-sectional analyses were conducted on baseline questionnaires from an ongoing prospective cohort study. Setting Dutch Olympic athletes from the Netherlands Olympic Committee*Netherlands Sports Confederation (NOC*NSF). Patients (or Participants) A total of 203 elite athletes were enrolled (mean age at recruitment was 27 years; mean sports career duration was 8 years). Interventions (or Assessment of Risk Factors) The assessment of risk indicators was based on validated scales. Main Outcome Measurements Symptoms of common mental disorders were assessed with validated scales. Results Prevalence (4-week) of symptoms of common mental disorders (not clinically diagnosed) ranged from 6% for adverse alcohol use to 45% for anxiety/depression. A higher number of past severe injuries, higher number of past surgeries, higher number of recent life events, higher level of career dissatisfaction and lower level of social support were related to the occurrence of symptoms of common mental disorders among elite athletes. Conclusions On average, the 4-week prevalence of CMD as shown in our study among Dutch elite athletes were similar to the ones found among athletes from other sports disciplines and does compare with the lifetime prevalence estimates in the general population of the Netherlands.
Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers.
Authors: Filip Janku, Helen J. Huang, Nishma M. Ramzanali, David S. Hong, Daniel D. Karp, Siqing Fu, Xuyu Cai, Yue Zhao, Neeraj Salathia, Jill Waters, Li Liu, Funda Meric-Bernstam, Gordon B. Mills, Jian-Bing Fan
Journal: Journal of Clinical Oncology (2015)

e22168 Background: Plasma cfDNA offers an easily obtainable source of DNA for molecular analysis, which provides an attractive alternative to tumor tissue testing. Novel ultrasensitive multiplex technologies are needed for further implementation of cfDNA testing in personalized cancer therapy. Methods: We have developed an ultra-deep next-generation sequencing method for detection of somatic alterations in 30 to 58 common cancer related genes in plasma cfDNA. Each cfDNA fragment was uniquely barcoded and amplified prior to Illumina target enrichment workflow, followed by ultra-deep sequencing ( > 10,000X). Proprietary data processing and analysis tools were developed to enable sensitive detection of rare mutant molecules over high wild-type background (detection of 1 in 1,000 - 10,000 molecules). Results were compared to molecular analysis of archival primary or metastatic tumor tissue obtained at different points of clinical care from a CLIA-certified laboratory. Results: Initially, cfDNA was extracted from plasma samples of 24 patients with advanced cancers (melanoma, n = 9; colorectal, n = 5; non-small cell lung [NSCLC], n = 2; thyroid, n = 2; other, n = 6) and 5ng were used for BRAF mutation analysis. BRAF mutations were detected in 71% (17/24) of plasma samples and in 88% (21/24) of archival tumor samples (CLIA), resulting in concordance in 87% (20/24) of cases. Subsequently, we extracted plasma samples from additional 46 patients with advanced cancers (colorectal, n = 13; melanoma, n = 5; NSCLC, n = 8; breast, n = 4; thyroid, n = 3; others, n = 13) and tested 14-30ng of cfDNA for the presence of alterations in 30 to 58 cancer related genes. Both ultra-deep sequencing of plasma cfDNA and standard tissue sequencing (CLIA) detected median of 2 alterations per patient and dominant oncogenic alterations previously detected in the tumor tissue were also found in plasma cfDNA. The profile and quantity of cfDNA alterations dynamically changed in patients on therapy. Conclusions: Detecting common oncogenic alterations using ultra-deep sequencing of plasma cfDNA is feasible with an acceptable level of concordance with testing of tumor tissue and should be further investigated for testing in patients with advanced cancer.
Prevalence of endothelial nitric oxide synthase genepolymorphisms in patients with atopic asthma
Authors: Lydie Izakovičová Hollá, Dana Bučková, Viera Kuhrová, Andrea Stejskalová, Hana Francová, Vladimír Znojil, Jiří Vácha
Journal: Allergy (2002)

Asthma is a common multifactorial disease, the aetiology of
which is attributable to both environmental and genetic
factors. The endothelial nitric oxide synthase (NOS3) gene has
been implicated in asthma pathogenesis. This study investigated
associations of 27 base-pair tandem repeat polymorphism in
intron 4 and the Glu298Asp (G894T) variant of the NOS3 gene
with atopic asthma in a Czech population. Polymerase chain
reaction was used to determine the NOS3 genotypes in subjects
with atopic asthma (n=163) and random controls (n=209). The
NOS3 allele of genotype distributions did not differ
significantly between the control and asthma groups. However,
the common genotype (bb) of the NOS3 polymorphism in intron 4
was found to be significantly associated with total IgE levels
(P=0.004). In one atopic patient, we identified an additional
27-bp repeat in the NOS3 gene (NOS3c), which occured in
heterozygous combination with the NOS3b allele (NOS3b/c
genotype). In addition, we describe a new polymorphism (A5495G)
in the NOS3 gene, which was in almost complete linkage
disequilibrium with the NOS3 repeat polymorphism in intron 4.
The Glu298Asp variant was not associated with asthma and/or
related atopic phenotypes in our study. Neither the NOS3 'b'
allelle nor the NOS3 'b/b' genotype showed any general
association with atopic asthma, but they were associated with
atopy-related phenotypes. We conclude that the NOS3 gene
polymorphisms may act as disease modifiers in atopic asthma
phenotype in our population.
EXPLORACIÓN DUCTAL PANCREÁTICA EN PACIENTES CON COLECCIONES PANCREÁTICAS DRENADAS ENDOSCÓPICAMENTE POR VÍA TRANSMURAL: RIESGOS Y BENEFICIOS
Authors: JJ Vila, E Sainza, A Cebrián, C Saldaña, C Prieto, I Fernandez-Urién, B González De La Higuera, D Ruiz-Clavijo, J Jiménez-Pérez
Journal: Endoscopy (2015)

Introducción: La valoración ductal pancreática en pacientes con colecciones pancreáticas drenadas por vía transmural es beneficiosa pero controvertida y autores recomiendan no retirar las prótesis transmurales.
Monitoring blood pressure for 30 minutes reduces unnecessary hypertension treatment, finds study
Authors: Susan Mayor
Journal: BMJ (2017)

Using automated blood pressure monitoring over 30 minutes reduces the number of patients requiring hypertension treatment and those needing an increased dose of existing hypertension treatment, a primary care study has shown.

Previous research has indicated that up to one third of patients found to be hypertensive in a clinical setting have white coat hypertension, with raised blood pressure that falls to within the normal range in other settings. Many of these patients are treated for hypertension so the new study investigated whether monitoring blood …
ASSOCIATION OF ANKLE BRACHIAL INDEX WITH LIMB OUTCOMES IN PERIPHERAL ARTERY DISEASE: A COMMUNITY-BASED STUDY
Authors: Vishnu Priya Mallipeddi, Iftikhar Kullo, Naveed Afzal, Manju Kalra, Bradley Lewis, Christopher Scott, Hongfang Liu, Thom Rooke, Adelaide Arruda-Olson
Journal: Journal of the American College of Cardiology (2017)
Brain distribution of the MDM2 inhibitor, RG7112: Single dose escalation and repeated doses studies.
Authors: Lauriane Goldwirt, Maite Verreault, Camille Levasseur, Charlotte Schmitt, Jeremy Guehennec, Marianne Labussiere, Sam Haidar, Karima Mokhtari, Samia Mourah, Khe Hoang-Xuan, Marc Sanson, Patrick Y. Wen, Keith L. Ligon, Jean-Yves Delattre, Ahmed Idbaih
Journal: Journal of Clinical Oncology (2015)

e13582 Background: MDM2 amplification seen in 14% of glioblastoma (GBM) is a potential therapeutic target. We have shown that RG7112, an oral non-genotoxic MDM2 antagonist, crosses the blood brain barrier and shows in vivo efficacy in GBM mouse models (repeated dose 100 mg/kg QD). The present work investigated the Brain distribution of RG7112 to optimize the scheme delivery toward increased efficacy. Methods: To investigate Brain distribution, single dose escalation (SDE) and repeated doses (RD) studies were conducted. For both studies : (i) RG7112 was delivered to healthy Swiss mice, (ii) RG7112 Plasma and Brain concentrations were quantified using LC-MS/MS method. The AUC0-t were calculated using the trapezoidal rule and compared using Bailer method. Correlations were assessed using the Pearson product-moment method. SDE study enrolled 21 mice to test 3 doses of RG7112 (10, 100, and 200 mg/kg once) at 7 time-points (0, 1, 2, 4, 8, 16, and 24 hours after treatment). RD study enrolled 21 mice to test 100 mg/kg of RG7112 QD for 15 days. Mice were sacrificed at 7 time-points (0, 1, 2, 4, 8, 16, and 24 hours after the last treatment). Each time-point included 3 mice. Results: RG7112 Dose and Plasma-exposure were linearly correlated (AUC0-t; R2= 1.000; p < 0.01). Although a trend is observed, RG7112 Brain-exposure was non-significantly correlated to RG7112 Plasma-exposure (AUC0-t; R2= 0.997; p = 0.051). No saturation of Brain-exposure was observed during SDE study. An increase of Brain-exposure was observed in RD study. Indeed, under steady-state conditions, AUC0-t Day15/Day1 ratio reached 1.3 and 2.8 in Plasma and Brain, respectively. Conclusions: Our study supports investigations repeated dose for 15 days (or longer) of 200 mg/kg QD (or higher) of RG7112 to get better Brain-distribution. Assessments of changes in p53 pathway targets and survival of GBM bearing mice are ongoing.RG7112 was provided by Hoffmann-La Roche. This work is part of the GlioTex project funded by La Fondation ARC.
Dendritic Cells Vaccination in BCR/ABL-Positive Chronic Myeloid Leukemia - Final Results of a Phase I/II Study.
Authors: Jörg Westermann, Joachim Kopp, Antje van Lessen, Ann Hecker, Gökben Baskaynak, Philipp Le Coutre, Constanze Döhner, Hartmut Döhner, Bernd Dörken, Antonio Pezzutto
Journal: Blood (2004)
Functional improvement measured by the six-minute walk test after chemotherapy in cardiac AL amyloidosis.
Authors: Ilka Decker, Oluchi Ukaegbu, Stacey Goodman, Daniel John Lenihan, Sharon Phillips, Robert Hoffman, Sara Horst, Rebecca Hung, Adetola Kassim, Shelton Lacy, Anthony Langone, Kevin T. McDonagh, Kyle Rawling, Samuel Rubinstein, Mark Steele, Robert F. Cornell
Journal: Journal of Clinical Oncology (2015)

e19539 Background: Light chain amyloidosis (AL) is characterized by the accumulation of misfolded proteins that deposit in tissue causing multisystem organ dysfunction. Current treatments target plasma cells which produce pathogenic proteins. Development of amyloid protein directed monoclonal antibody therapy has led to increased need for objective measurements of clinical response. The 6 minute walk test (6MWT) has been used to monitor disease severity in clinical trials of heart failure. We hypothesized that improvement in 6MWT would correlate with improvement of cardiac biomarkers in AL patients. Methods: This was a retrospective analysis of 22 AL patients, 20 of which had definitive cardiac involvement, who completed 6MWT at diagnosis and at the end of planned initial chemotherapy. Additional cardiac assessments included NYHA class, BNP, troponin I and left ventricular ejection fraction (LV EF). Results: The majority (95%) received bortezomib-based initial chemotherapy and 59% (n = 13) underwent autologous hematopoietic cell transplant (AHCT). Patients were reassessed a median of 13.5 mo from baseline. The median improvement in 6MWT was 90 meters (range: 15-365). Overall 77% (n = 17) had improvement in 6MWT distance, 14% (n = 3) had declines in 6MWT distance and 9% (n = 2) unchanged. Improvement in 6MWT distance was strongly associated with decreases in BNP, troponin I and NYHA class (all p < 0.01). No association was found between change in 6MWT and LV EF or hematological response. Conclusions: In AL patients with cardiac involvement, the 6MWT can be used as an objective marker of functional improvement which complements cardiac biomarkers of AL cardiac response. Larger sample size and prospective assessment will be needed to determine the possible association, if any, between 6MWT and hematological and organ responses. Baseline Characteristics N = 22 Male sex – no. (%) 15 (68) Age – yr, range 59 (35-69) Light Chain – no. (%) λ 13 (59) κ 8 (36) Biclonal 1 (5) NYHA class – no. (%) 1 4 (18) 2 8 (36) 3 9 (41) 4 1 (5) Median BNP, pg/ml, range 550 (122-4476) Median trop I, ng/ml, range 0.1 (0.01-3.02) Median LV EF, range (%) 59 (25-75) Median 6MWT distance (m), range 182 (0-488) Chemotherapy – no. (%) Bortezomib-based 21 (95) AHCT 13 (59)
CAN NECROTIC CORE VOLUME EXPLAIN ISCHEMIA CORONARY STENOSIS MISMATCH IN SOME CASES?
Authors: Amir Ali Ahmadi, Jonathan Leipsic, Kristian Oevrehus, Sara Gaur, Angel Sanz Salvo, Gina LaRocca, Pedro Moreno, Farah Lajam, Bjarne Norgaard, Jagat Narula
Journal: Journal of the American College of Cardiology (2017)
Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)
Authors: Arjan A. van de Loosdrecht, Dana A Chitu, Eline MP Cremers, Theresia M Westers, Canan Alhan, Heleen Visser-Wisselaar, Annelies Verbrugge, Petra Muus, Inge de Greef, Pierre W Wijermans, Joop H. Jansen, Saskia K. Klein, Edo Vellenga, Marie-Cecile Legdeur, Wendy Deenik, Mojca jongen-Lavrencic, Rien van Marwijk-Kooy, Bea Tanis, Jurgen Wegman, Tanja van Maanen, Gert Ossenkoppele
Journal: Blood (2016)